Use of Carnitine to Children with Carditis on the Background of Community - Acquired Pneumonia

Pneumonia in children is one of the urgent problems in pediatrics, which is determined by the continuing high incidence and severe prognosis, especially in young children. The aim of the study was to evaluate the effectiveness of the use of carnitine in the treatment and prevention of myocarditis in children with community – acquired pneumonia. We examined 80 children aged 1 to 7 years with pneumonia, which we divided into 2 groups. Group I (control) included 40 children who were on standard treatment. Group II (main) included 40 sick children with pneumonia, who had a violation of the cardiovascular system and parenterally received the drug carnitine. The results obtained underline that the use of carnitine for pneumonia in children reduces the risk of severe unwanted heart complications and reduces the length of hospital stay by an average of 1.8 bed-days in comparison with standard therapy.